RESUMEN
Although the metastasic breast cancer is still an incurable disease, recent advances have increased significantly the time to progression and the overall survival. However, too much information has been produced in the last 2 years, so a well-based guideline is a valuable document in treatment decision making. The SEOM guidelines are intended to make evidence-based recommendations on how to manage patients with advanced and recurrent breast cancer to achieve the best patient outcomes based on a rational use of the currently available therapies. To assign a level of certainty and a grade of recommendation the United States Preventive Services Task Force guidelines methodology was selected as reference
No disponible
Asunto(s)
Humanos , Femenino , Neoplasias de la Mama/patología , Recurrencia Local de Neoplasia/patología , Metástasis de la Neoplasia/patología , Recurrencia Local de Neoplasia/terapia , Neoplasias de la Mama/terapia , Calidad de Vida/psicología , Pautas de la Práctica en MedicinaRESUMEN
The coming into force of Directive 2001/20/EC represented a step forward in harmonising clinical trial regulation in European countries, guaranteeing a uniform protection of subjects participating in clinical research across Europe. However, it led to a disproportionate increase in the bureaucratization, and thus, it became evident that procedures needed to be simplified without detriment to patients safety. Thus, Regulation 536/2014, that repealed Directive 2001/20/EC, with the aim of decreasing the growing bureaucratization and stimulating clinical research in Europe, established simplified procedures, such as regulating a common procedure for authorising trials in Europe, the institution of strict assessment timelines, or the definition of new concepts, such as «low-intervention clinical trial». The legal form of a Regulation allowed the norm to be directly applied to Member States without the need for transposition. By means of the new Royal Decree, the national legislation is adapted to make the application of the regulation feasible and it allows the development of the aspects that the Regulation leaves to national legislation. Both documents seek to stimulate clinical research with medicinal products to foster knowledge, facilitate transparency, and reinforce subjects safety. This will surely be the case, but with this revision, we will look at the novelties and key aspects that are most relevant to investigators and we will analyse the consequences for all parties involved in clinical research (AU)
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Ensayos Clínicos como Asunto/legislación & jurisprudencia , Libre Elección del Paciente/normas , Intervención Legal , Estudios Controlados Antes y Después/legislación & jurisprudencia , Compensación y Reparación/legislación & jurisprudencia , 51725/legislación & jurisprudencia , Investigación Biomédica/legislación & jurisprudencia , Comités de Monitoreo de Datos de Ensayos Clínicos/legislación & jurisprudencia , Regulación y Fiscalización en Salud , Declaración de Helsinki , Unión Europea/organización & administraciónRESUMEN
PURPOSE: To estimate the cost per skeletal-related event (SRE) in patients with bone metastases secondary to solid tumours in the Spanish healthcare setting. METHODS: Patients diagnosed with bone metastases secondary to breast, prostate or lung cancer were included in this multicentre, observational study. SREs are defined as pathologic fracture (vertebral and non-vertebral fracture), radiation to bone, spinal cord compression or surgery to bone. Health resource utilisation associated with these events (inpatient stays, outpatient, emergency room and home health visits, nursing home stays and procedures) were collected retrospectively for all SREs that occurred in the 97 days prior to enrolment and prospectively during follow-up. Unit costs were obtained from the 2010 eSalud healthcare costs database. RESULTS: A total of 93 Spanish patients with solid tumours were included (31 had breast cancer, 21 prostate cancer and 41 lung cancer), contributing a total of 143 SREs to this cost analysis. Inpatient stays (between 9.0 and 29.9 days of mean length of stay per inpatient stay by SRE type) and outpatient visits (between 1.7 and 6.4 mean visits per SRE type) were the most frequently reported types of health resources utilised. The mean cost per SRE was between
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Neoplasias Óseas/economía , Neoplasias de la Mama/patología , Costos y Análisis de Costo , Neoplasias Pulmonares/patología , Neoplasias de la Próstata/patología , EspañaRESUMEN
INTRODUCTION: The randomised controlled trial BCIRG001 has recently demonstrated that docetaxel in combination with doxorubicin and cyclophosphamide (TAC) has better efficacy than the standard treatment (FAC, i.e., 5-fluorouracil, doxorubicin and cyclophosphamide) in the adjuvant treatment of patients with node-positive breast cancer. The cost-effectiveness of TAC vs. FAC in the Spanish setting is analysed. PATIENTS AND METHODS: Clinical outcomes from trial BCIRG001 were combined with Spanish costs and longterm efficacy of FAC and TAC extrapolated up to 5 years by means of a Markov model. Results are shown as cost per life year gained (C/LYG) and cost per quality-adjusted life year (C/QALY). Costs and effects were discounted at a rate of 3%. RESULTS: Mean survival was 17.8 and 16.5 years for TAC and FAC, with total costs of euro14,611 and euro11,586, respectively. The results of the cost-effectiveness analysis showed that TAC achieves a C/LYG and a C/QALY of only euro2345 and euro2631, respectively. Sensitivity analysis confirmed the robustness of the results. CONCLUSIONS: Combined therapy based on docetaxel (TAC) is not only an effective option, but also presents a favourable cost-effectiveness ratio, clearly below the Spanish efficiency threshold in all the scenarios considered.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/economía , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/economía , Fluorouracilo/economía , Taxoides/economía , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/mortalidad , Análisis Costo-Beneficio , Ciclofosfamida/administración & dosificación , Ciclofosfamida/efectos adversos , Docetaxel , Doxorrubicina/administración & dosificación , Doxorrubicina/efectos adversos , Femenino , Fluorouracilo/efectos adversos , Fluorouracilo/uso terapéutico , Humanos , Modelos Económicos , Años de Vida Ajustados por Calidad de Vida , Taxoides/administración & dosificación , Taxoides/efectos adversosRESUMEN
No disponible
Asunto(s)
Humanos , Neoplasias/complicaciones , Trastornos Nutricionales/epidemiología , Oncología Médica/tendencias , Atención Integral de Salud/tendenciasRESUMEN
No disponible
Asunto(s)
Humanos , Trastornos Nutricionales/fisiopatología , Neoplasias/complicaciones , Desnutrición/fisiopatología , Anorexia/epidemiología , Desnutrición Proteico-Calórica/epidemiología , Caquexia/epidemiología , Pérdida de Peso , Antineoplásicos/efectos adversos , Radioterapia/efectos adversosRESUMEN
No disponible
Asunto(s)
Humanos , Neoplasias/complicaciones , Trastornos Nutricionales/epidemiología , Estado Nutricional , Desnutrición Proteico-Calórica/complicaciones , Calidad de Vida , Resultado del Tratamiento , Tolerancia a Medicamentos , Cumplimiento de la Medicación/estadística & datos numéricos , Indicadores de Morbimortalidad , Caquexia/fisiopatología , Costos de la Atención en Salud/estadística & datos numéricosRESUMEN
No disponible
Asunto(s)
Humanos , Neoplasias/complicaciones , Trastornos Nutricionales/diagnóstico , Evaluación Nutricional , Estado Nutricional , Desnutrición/diagnóstico , Tamizaje Masivo/métodos , Diagnóstico Precoz , Pérdida de Peso/fisiología , Trastornos de Alimentación y de la Ingestión de Alimentos/fisiopatologíaRESUMEN
No disponible
Asunto(s)
Humanos , Neoplasias/complicaciones , Trastornos Nutricionales/epidemiología , Desnutrición/dietoterapia , Terapia Nutricional/métodos , Evaluación de Resultados de Intervenciones Terapéuticas , Apoyo Nutricional/métodos , Factores de Riesgo , Anorexia/dietoterapia , Náusea/dietoterapia , Estreñimiento/dietoterapia , Trastornos de Deglución/dietoterapiaRESUMEN
No disponible
Asunto(s)
Humanos , Trastornos de Alimentación y de la Ingestión de Alimentos/tratamiento farmacológico , Estimulantes del Apetito/uso terapéutico , Anorexia/tratamiento farmacológico , Caquexia/tratamiento farmacológico , Neoplasias/complicaciones , Trastornos Nutricionales/epidemiología , Pérdida de Peso , Progestinas/uso terapéutico , Corticoesteroides/uso terapéuticoRESUMEN
No disponible